Naturally Splendid Announces Advisory Board Addition

Naturally Splendid Enterprises Ltd. (FSE: 50N) (TSXV: NSP) (OTCQB: NSPDF) ("Naturally Splendid", "NSE" or "the Company") is pleased to announce the appointment of Mr. Kris Tarr to the Advisory Board, assisting in the area of e-commerce and online marketing.

Mr. Tarr's professional career has spanned almost three decades as an Information Technology and Internet Marketing Consultant. Kris has held several senior marketing management and IT executive positions, applying his decades of experience in technology, management and leadership to deliver business results for organizations in the high tech, pharmaceutical, tourism, entertainment, online gaming and real estate sectors.

Mr. Tarr has worked for globally recognized organizations such as Coca Cola, Disney and Nickelodeon. As a consultant he has guided over a hundred small and medium-size businesses developing and implementing online, e-commerce strategies.

Settling in Vancouver, Canada, Kris focused on Internet Marketing with an emphasis on SEO and Social Media Automation for the online gaming industry, including a position as Senior SEO Strategist for Bodog, a major online gaming brand. Kris has also held the positions of ITSM Head, CTO and IT Solutions Provider at Oriental Game, Asia's leading online gaming solutions provider.

Kris has started numerous lucrative business ventures and has built and operated many successful search engines including a property management franchise. He co-founded Waveless Websystems Inc. where he developed eCommerce solutions for the home building industry, which led him to Southeast Asia to expand the company's software development team.

Mr. Tarr states, "I am passionate about turning website ideas into successful online businesses utilizing my many years of experience in web application development and online marketing. I look forward to applying these skills to deliver a strong focus on social media marketing, organic search strategies, user experience and conversion optimization for the many brands at Naturally Splendid."

The on-going pandemic has altered many activities including daily shopping with more and more consumers resorting to online shopping for their purchases. Studies predict penetration rates, which are currently at 15 percent, are expected to increase to 25 percent by 2025, making a 67 percent increase in online sales in just five years.

Naturally Splendid CEO, Mr. J. Craig Goodwin states, "We are most fortunate to have Kris join our team. Online business has never been more important than it is today. The on-going pandemic has accelerated a shift in consumer buying trends in a manner not seen previously. We look forward to working with Kris to optimize our online presence and e-commerce platforms."

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573.

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Contact Information
Naturally Splendid Enterprises Ltd.
(TSXV: NSP) (OTCQB: NSPDF) (FSE: 50N)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68149

News Provided by Newsfile via QuoteMedia

The Conversation (0)
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×